Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 220

  • 3 926 clinical trials
  • 1 543 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 926 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 926 clinical trials

Plasma cell myeloma

Not recruiting

Study on Isatuximab and CellProtect for Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Evencaleucel
  • Sponsor:Karolinska Institutet

Non-small cell lung cancer

Not recruiting

Study Comparing Cemiplimab to Platinum-Based Chemotherapy for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Regeneron Pharmaceuticals Inc.

Glioblastoma multiforme

Not recruiting

Study of Berubicin versus lomustine in adult patients with recurrent Glioblastoma Multiforme after first-line treatment failure

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lomustine
  • Sponsor:Cns Pharmaceuticals Inc.

Rectal cancer

Not recruiting

Study Comparing Short Course Radiotherapy and Chemoradiotherapy with Fluorouracil, Calcium Folinate, and Capecitabine for Intermediate and High-Risk Rectal Cancer Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Goethe University Frankfurt

Pancreatic carcinoma

Not recruiting

Study on Sonoporation-Enhanced Treatment with Gemcitabine, Nab-Paclitaxel, and FOLFIRINOX for Patients with Inoperable Pancreatic Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Helse Bergen HF

Metastases to central nervous system+1

Not recruiting

Study on the Effects of Losartan Potassium on Brain Tumors in Patients with Glioblastoma or Brain Metastases from Non-Small-Cell Lung Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Losartan Potassium
  • Sponsor:Oslo University Hospital HF

Non-small cell lung cancer

Not recruiting

Study of Cemiplimab and Chemotherapy Combination for Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Regeneron Pharmaceuticals Inc.

Colorectal cancer metastatic

Not recruiting

Study on Personalized Treatment for Metastatic Colorectal Cancer Using Regorafenib for Patients with Advanced Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Regorafenib
  • Sponsor:Centre Hospitalier Universitaire De Rennes

Colorectal cancer metastatic

Not recruiting

Study on Tocotrienol and Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Lillebaelt Hospital

Oesophageal carcinoma

Not recruiting

Study on the Safety of Radiation and Nivolumab for Patients with Esophageal Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Oslo University Hospital HF

Neoplasm

Not recruiting

Study of Vusolimogene Oderparepvec and Nivolumab for Patients with Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Replimune Group Inc.

Colon cancer

Not recruiting

Study on the Effects of Capecitabine and Oxaliplatin in Patients with Locally Advanced Colon Cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Lillebaelt Hospital

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab467 clinical trialsCarboplatin344 clinical trialsCisplatin288 clinical trialsPaclitaxel266 clinical trialsFluorouracil239 clinical trialsOxaliplatin230 clinical trialsNivolumab218 clinical trialsDexamethasone169 clinical trialsDurvalumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.